Brokerages Set Envista Holdings Co. (NYSE:NVST) Price Target at $43.67

Shares of Envista Holdings Co. (NYSE:NVST) have been given an average rating of “Buy” by the eight analysts that are presently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $43.67.

Separately, Piper Sandler boosted their target price on shares of Envista from $45.00 to $47.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 4th.

In other Envista news, SVP Jeffrey Kappler sold 1,717 shares of the firm’s stock in a transaction on Friday, July 16th. The stock was sold at an average price of $42.00, for a total value of $72,114.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Mark E. Nance sold 4,321 shares of Envista stock in a transaction on Tuesday, September 14th. The stock was sold at an average price of $44.01, for a total value of $190,167.21. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,405 shares of company stock worth $703,447. 0.82% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Macquarie Group Ltd. grew its stake in Envista by 771.4% during the 2nd quarter. Macquarie Group Ltd. now owns 4,015,893 shares of the company’s stock worth $173,527,000 after buying an additional 3,555,062 shares during the last quarter. Boston Partners grew its stake in shares of Envista by 48.8% in the second quarter. Boston Partners now owns 2,945,015 shares of the company’s stock worth $127,358,000 after purchasing an additional 966,446 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Envista by 149.7% during the second quarter. Bank of New York Mellon Corp now owns 1,561,755 shares of the company’s stock valued at $67,485,000 after buying an additional 936,393 shares in the last quarter. Smith Asset Management Group LP boosted its stake in Envista by 3,606.1% during the first quarter. Smith Asset Management Group LP now owns 644,039 shares of the company’s stock valued at $26,291,000 after buying an additional 626,661 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Envista by 4.2% during the second quarter. Vanguard Group Inc. now owns 14,897,130 shares of the company’s stock valued at $643,705,000 after buying an additional 598,953 shares in the last quarter.

NYSE:NVST traded down $0.95 during trading hours on Monday, hitting $41.58. 1,113,123 shares of the company were exchanged, compared to its average volume of 1,866,474. The stock has a market capitalization of $6.71 billion, a price-to-earnings ratio of 23.36, a PEG ratio of 0.80 and a beta of 1.92. Envista has a 52-week low of $22.51 and a 52-week high of $46.52. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.12 and a quick ratio of 0.85. The company’s 50 day moving average price is $41.98 and its 200-day moving average price is $42.48.

Envista (NYSE:NVST) last released its earnings results on Tuesday, August 3rd. The company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.09. The company had revenue of $740.10 million for the quarter, compared to the consensus estimate of $705.75 million. Envista had a net margin of 10.84% and a return on equity of 9.72%. On average, equities analysts predict that Envista will post 1.96 earnings per share for the current year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands.

Featured Article: Determine Your Level of Risk Tolerance

Analyst Recommendations for Envista (NYSE:NVST)

Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.